Loading…

Immatics N.V.IMTXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

German biotech engineering T-cell receptor (TCR) bispecific drugs and cell therapies targeting cancer antigens like PRAME.

Momentum laggard 14
Mkt cap
$913M
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$7.78M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 11.6%
Hurdle
n/a
no reverse DCF
Next earnings
126 days
24 Mar 2027
Close · USD$6.10
1D-3.0%
1W-8.8%
1M-18.8%
3M-28.6%
6M-45.6%
YTD-41.9%
1Y-35.6%
ATR %7.4%
Beta1.39
52w lowhigh50.9% off high

What Immatics does

German biotech engineering T-cell receptor (TCR) bispecific drugs and cell therapies targeting cancer antigens like PRAME.

Has no approved product, so it lives on upfront and milestone payments from collaborations with large drug makers, plus share sales. Its main in-house programs target PRAME, a protein many tumours carry, while partners fund other candidates. Dutch-registered, with its research and operations based in Germany and the US.

Products and services

  • Anzu-cel (IMA203, PRAME-directed TCR-T cell therapy)
  • IMA402 (PRAME TCER bispecific)
  • IMA401 (MAGEA4/8 TCER bispecific, with Bristol Myers Squibb)

Where it sits in the supply chain

  • Biopharma R&D
  • TCR-bispecific/cell-therapy platform
  • Partnered oncology development (BMS…

What could go right

  • Anzu-cel pivotal trial progress and filing plans
  • Partner payments from Bristol Myers Squibb and Moderna

What could go wrong

  • Complex cell-therapy manufacturing/logistics
  • Binary clinical trial risk

Moat: narrow (IP / patents, process know-how). Proprietary TCR-discovery platform is licensed to multiple large pharma partners for milestones.

Headquarters: Tübingen, Germany · Founded: 2000 · Employees: 656

Named competitors

Immatics at a glance

Size Immatics (IMTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $913M, the 2286th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.10 on 18 Nov 2026.

Performance Over six months the shares fell 45.6%, against -20.9% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue fell 44.5% over the last twelve months (peer median +2.4%); the operating margin is -588.5% (peer median 8.8%).

Valuation It trades at 8.5× enterprise value to sales against a peer median of 3.5× (3rd most expensive of 18).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 81IMTX 55
Six months, rebased to 100: Immatics against the median of its 20 peers (local-currency closes).

Immatics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$50.5M$54.5M$169M$58.4M$182M
Revenue growth—-68%+189%-68%—
EBITDA-$283M-$197M-$28.6M-$103M$38.8M
Net income-$269M-$222M$16.5M-$102M$39.4M
Free cash flow-$259M-$207M-$189M-$13.6M$99.2M
Capital expenditure$3.97M$7.68M$17.8M$33.5M$6.53M
Total debt$53.7M$18.4M$18.6M$38.0M$33.6M

Quarterly statements and history in the cockpit →

Immatics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%-20%0%+20%2595MLTX1795688553300401039200688177AKTS000597600252600422603538STAR2005SANOFICONR300294688759PHARMIMTX6-month return →1-month return →
Up and to the right = strong over both horizons. Immatics is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×20×40×60×25951795688553300401039200AKTS000597600422SANOFICONRIMTXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Immatics is the large dot.

Immatics competitors and peer comparison

Head to head with its named competitors (IMTX vs IMCR vs IOVA)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Immatics IMTX$913M-46%-44%-589%8.5×n/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR$1.44B-7%+13%-7%2.3×n/a
Iovance Biotherapeutics IOVA$3.46B+111%+51%-61%8.3×n/a

How Immatics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Immatics against its 20 peers (data as of 18 Nov 2026)
MeasureIMTXPeer medianRank in peer set
1-month return-18.8%-9.1%4th lowest of 21
6-month return-45.6%-20.9%3rd lowest of 20
Distance from 52-week high-50.9%-46.6%8th lowest of 21
Revenue growth (TTM)-44.5%+2.4%2nd lowest of 18
Operating margin-588.5%8.8%2nd lowest of 18
EV / Sales8.5×3.5×3rd most expensive of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Immatics IMTXUnited States$913M-46%-44%-589%8.5×n/an/a
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%55.9×n/an/a
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%2.6×-3.7%+13.8%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%5.2×9.1%+13.4%
Oscotec 039200.KSSouth Korea$923M-32%+510%59%7.5×-10.2%+18.1%
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%6.5×n/an/a
Aktis Oncology AKTSUnited States$895M-15%+337%-837%33.4×n/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%0.9×-7.6%-0.7%
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%4.5×10.3%-13.7%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%1.8×n/an/a
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%2.8×7.7%-6.9%
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%3.8×11.6%+4.9%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%2.0×17.6%+7.8%
SSY 2005.HKHong Kong$948M+8%-4%12%2.2×2.3%-0.5%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%8.3×17.7%+22.7%
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%2.5×n/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
Pharming PHARM.ASNetherlands$867M-6%+2%9%2.2×2.4%+12.4%

Questions

Who are Immatics's main competitors?
Named competitors: Immunocore (IMCR), Iovance Biotherapeutics (IOVA). The cockpit's measured peer set (industry) also includes Genfleet Therapeutics (Shanghai) (2595.HK), MoonLake Immunotherapeutics (MLTX), Lotus Pharmaceutical (1795.TW), Sichuan Huiyu Pharmaceutical (688553.SS), Zhejiang Garden Biopharmaceutical (300401.SZ), Oscotec (039200.KS).
Is Immatics expensive compared with its peers?
On ev / sales it trades at 8.5× against a peer median of 3.5×, 3rd most expensive of 18 in its peer set.
How has Immatics stock performed?
Over six months to 18 Nov 2026 the shares returned -45.6% against -20.9% for the median peer; over one year -35.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.